- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.11. | CHIMERIC THERAPEUTICS LIMITED: Constitution | - | ASX | ||
| 12.11. | CHIMERIC THERAPEUTICS LIMITED: Results of Meeting | 1 | ASX | ||
| CHIMERIC THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 11.11. | CHIMERIC THERAPEUTICS LIMITED: AGM Presentation and CEO Appointment | - | ASX | ||
| 05.11. | CHIMERIC THERAPEUTICS LIMITED: Notice under section 708A | 1 | ASX | ||
| 05.11. | CHIMERIC THERAPEUTICS LIMITED: Application for quotation of securities - CHM | 1 | ASX | ||
| 03.11. | CHIMERIC THERAPEUTICS LIMITED: Notice of Extraordinary General Meeting December 2024 | - | ASX | ||
| 30.10. | CHIMERIC THERAPEUTICS LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | - | ASX | ||
| 24.10. | CHIMERIC THERAPEUTICS LIMITED: Investor webinar | 2 | ASX | ||
| 24.10. | CHIMERIC THERAPEUTICS LIMITED: Dose finding complete in ADVENT-AML Phase 1b clinical trial | - | ASX | ||
| 24.10. | CHIMERIC THERAPEUTICS LIMITED: Application for quotation of securities - CHM | - | ASX | ||
| 22.10. | CHIMERIC THERAPEUTICS LIMITED: Prospectus | - | ASX | ||
| 21.10. | CHIMERIC THERAPEUTICS LIMITED: Reinstatement to Official Quotation | - | ASX | ||
| 21.10. | CHIMERIC THERAPEUTICS LIMITED: Corporate Governance Statement and Appendix 4G | 1 | ASX | ||
| 21.10. | CHIMERIC THERAPEUTICS LIMITED: ESG Report | 1 | ASX | ||
| 21.10. | CHIMERIC THERAPEUTICS LIMITED: Annual Report 2024 | 2 | ASX | ||
| 21.10. | CHIMERIC THERAPEUTICS LIMITED: Proposed issue of securities - CHM | - | ASX | ||
| 21.10. | CHIMERIC THERAPEUTICS LIMITED: Proposed issue of securities - CHM | 1 | ASX | ||
| 21.10. | CHIMERIC THERAPEUTICS LIMITED: $5 million Placement to progress CHM CDH17 trial | - | ASX | ||
| 16.10. | CHIMERIC THERAPEUTICS LIMITED: Change in substantial holding - PH | 1 | ASX | ||
| 14.10. | CHIMERIC THERAPEUTICS LIMITED: Notice of Annual General Meeting | 1 | ASX |
Seite:
1 2 3 Weiter >>
51 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ADMA BIOLOGICS | 21,370 | 0,00 % | Adma Biologics Aktie: Erholung nach starkem Kursrückgang | ||
| RECURSION PHARMACEUTICALS | 6,040 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| EVOTEC | 9,865 | -0,40 % | Evotec: Extreme Ausschläge | Größer könnten die Gegensätze wohl kaum sein. Die Aktie von Evotec hat im zurückliegenden Jahren einen massiven Einbruch erfahren. Auf 52-Wochen-Sicht gehört sie zu den schlechtesten Aktien im SDAX.... ► Artikel lesen | |
| QIAGEN | 40,180 | +3,45 % | Neue 6,00% Aktienanleihe mit Barriere auf QIAGEN in Zeichnung | München (www.anleihencheck.de) - Die Experten vom Zertifikate-Team der Bank Vontobel Europe AG bieten eine neue Aktienanleihe (ISIN DE000VC7RDU1/ WKN VC7RDU) mit Barriere auf die Aktie von QIAGEN (ISIN... ► Artikel lesen | |
| QUANTUM-SI | 1,400 | 0,00 % | Quantum-Si Inc - 8-K, Current Report | ||
| 89BIO | 7,980 | 0,00 % | 89bio, Inc.: 89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting 2024 | SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 59,76 | 0,00 % | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
| RELAY THERAPEUTICS | 4,660 | 0,00 % | Aktie von Relay Therapeutics erreicht 52-Wochen-Tief bei 5,59 US-Dollar | ||
| STRUCTURE THERAPEUTICS | 32,710 | 0,00 % | Structure Therapeutics reports Q3 results | ||
| SPRINGWORKS THERAPEUTICS | 37,440 | 0,00 % | SpringWorks started at outperform by Evercore ahead of FDA decision | ||
| 4D MOLECULAR THERAPEUTICS | 8,410 | 0,00 % | Analyst Expectations For 4D Molecular Therapeutics' Future | ||
| DYNE THERAPEUTICS | 30,000 | 0,00 % | Dyne Therapeutics: Leitender Vizepräsident veräußert Aktien im Wert von 77.127 US-Dollar | ||
| CULLINAN THERAPEUTICS | 12,580 | 0,00 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 | Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune diseases Cullinan will share details of global Phase... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 6,740 | 0,00 % | Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) | ||
| VERVE THERAPEUTICS | 4,550 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen |
CHIMERIC THERAPEUTICS LIMITED gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CHIMERIC THERAPEUTICS LIMITED finden Sie auf Wallstreet Online.
